From GlobeNewswire: 2024-05-14 16:05:00

BioAtla, Inc. released Phase 2 data for ozuriftamab vedotin in SCCHN, showing confirmed responses and a manageable safety profile, planning potential FDA meeting for registrational trial in 2H 2024. The evalstotug Phase 1 study is progressing well, with anticipated data readouts in 2Q and 2H 2024, seeking FDA guidance for first-line BRAF-mutated melanoma. Mecbotamab vedotin’s Phase 2 study in UPS is underway, with initial patient enrollment completed and further discussions with FDA planned for 2H 2024. CAB-EpCAM x CAB-CD3 Phase 1 data readout and Phase 2 study initiation expected in 2H 2024. FDA clearance was granted for CAB-Nectin4-ADC. Financially, BioAtla reported a cash balance of $80.6 million and expects to fund operations into 2H 2025. Management will host a conference call today at 4:30 PM Eastern Time to discuss these updates and more.



Read more at GlobeNewswire:: BioAtla Reports First Quarter 2024 Financial Results and